Autres langues RetinalGenix Technologies Inc.

Actions

RTGN

US76133Y1055

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 21:45:29 16/09/2026			Varia. 5j.	Varia. 1 janv.
3,990 ^USD	-0,25%		0,00%	+24,69%

14/08	RetinalGenix Technologies Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
20/05	RetinalGenix Technologies Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

14/08	RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/05	RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/04	RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
15/04	RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt
26/03	Retinalgenix Technologies Inc. Announces Resignation of Michael Cory Zwerling as Chief Financial Officer, Effective March 22, 2026
14/01	RetinalGenix Technologies Inc. Reports on Its Science and Mission in Light of New AI-Driven Retinal Mapping Study
14/01	RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
09/12	RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Chief Financial Officer, Effective January 1, 2026
09/12	RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Interim Chief Operating Officer, Effective January 1, 2026
09/12	RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO
14/11	RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
01/10/25	RetinalGenix Technologies Inc. and RGEN Inc. Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
01/10/25	RetinalGenix and RGEN Clinical Genotyping Lab partner to advance early disease detection
01/10/25	RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
25/09/25	RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
19/08/25	RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
30/06/25	RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
27/06/25	RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
27/06/25	RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
16/06/25	RetinalGeniX Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives
13/06/25	RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives
15/05/25	RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
05/05/25	RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
05/05/25	RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
31/03/25	RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2024